8-fluoro-6-hydroxy-3,4-dihydro-2(1H)-quinolinone | 143268-82-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 8-fluoro-6-hydroxy-3,4-dihydro-2(1H)-quinolinone
• 英文别名: 8-fluoro-6-hydroxy-3,4-dihydroquinolin-2(1H)-one；8-fluoro-6-hydroxy-3,4-dihydro-1H-quinolin-2-one
• CAS: 143268-82-0
• 化学式: C₉H₈FNO₂
• 分子量: 181.166
• InChiKey: BVJSJABWKQXITB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-fluoro-6-hydroxy-3,4-dihydro-2(1H)-quinolinone 在 sodium hydroxide 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 24.0h， 生成 6-[3-[benzyl(ethyl)amino]-2-hydroxypropoxy]-8-fluoro-1H-quinolin-2-one
  参考文献：
  名称：

  Novel positive inotropic agents: synthesis and biological activities of 6-(3-amino-2-hydroxypropoxy)-2(1H)-quinolinone derivatives

  摘要：

  A series of 6-(3-amino-2-hydroxypropoxy)-2(1H)-quinolinones has been synthesized and evaluated for positive inotropic activity on the canine heart. Some of these derivatives have a potent activity with none or negative chronotropic effect in isolated, blood-perfused dog heart preparations. They also display a high selectivity for positive inotropic effect over chronotropic and vasodilatory effects in anesthetized dogs. (+/-)-6-[2-Hydroxy-3-[(3-methoxybenzyl)amino]propoxy]-2(1H)-quinolinone (39) and (+/-)-6-[3-(3,4-dimethoxybenzyl)amino]-2-hydroxypropoxy]-2(1H)-quinolinone (40) were further investigated in conscious dogs. After iv administration, they did not affect heart rate or mean blood pressure at the dose producing a 50% increase in the peak of the first derivative of the left ventricular pressure. The compounds (39,OPC-18750, and 40,OPC-18790) are the most promising agents with desirable biological activities, and now are currently undergoing clinical evaluation.

  DOI：

  10.1021/jm00098a003
• 作为产物：
  描述：

  6-acetyl-3,4-dihydro-8-fluoro-2(1H)-quinolinone 在 甲醇 、 间氯过氧苯甲酸 、 sodium hydroxide 作用下， 以 氯仿 为溶剂， 反应 18.0h， 生成 8-fluoro-6-hydroxy-3,4-dihydro-2(1H)-quinolinone
  参考文献：
  名称：

  Selective NR2B Antagonists

  摘要：

  该披露通常涉及到I式化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是NR2B受体的配体，是其拮抗剂，可能对治疗中枢神经系统的各种疾病有用。

  公开号：

  US20130079338A1

文献信息

• [EN] COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS<br/>[FR] COMPOSÉS EN TANT QU'INHIBITEURS DE LA S-NITROSOGLUTATHION RÉDUCTASE
  申请人：N30 PHARMACEUTICALS LLC

  公开号：WO2012170371A1

  公开（公告）日：2012-12-13

  The present invention is directed to compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

  本发明涉及用作S-亚硝基谷胱甘肽还原酶（GSNOR）抑制剂的化合物，包括该化合物的制药组合物以及使用该化合物的方法。
• Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors
  申请人：Sun Xicheng

  公开号：US20130178499A1

  公开（公告）日：2013-07-11

  The present invention is directed to novel quinoline compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

  本发明涉及一种新型喹啉化合物，其可用作S-亚硝基谷胱甘肽还原酶（GSNOR）抑制剂，包括该化合物的制药组合物以及使用该化合物的方法。
• Compounds as S-Nitrosoglutathione Reductase Inhibitors
  申请人：N30 PHARMACEUTICALS, INC.

  公开号：US20140094465A1

  公开（公告）日：2014-04-03

  The present invention is directed to compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

  本发明涉及用作S-亚硝基谷胱甘肽还原酶（GSNOR）抑制剂的化合物，包括这种化合物的制药组合物，以及使用它们的方法。
• Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors
  申请人：Sun Xicheng

  公开号：US08921562B2

  公开（公告）日：2014-12-30

  The present invention is directed to novel quinoline compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

  本发明涉及一种新型喹啉化合物，其可用作S-亚硝基谷胱甘肽还原酶（GSNOR）抑制剂，包括这种化合物的制药组合物，以及制备和使用它们的方法。
• Selective NR2B antagonists
  申请人：Bristol-Myers Squibb Company

  公开号：US08841301B2

  公开（公告）日：2014-09-23

  The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

  本公开涉及公式I的化合物，包括其盐，以及使用这些化合物的组合物和方法。这些化合物是配体，是NR2B受体的拮抗剂，可能对中枢神经系统的各种疾病的治疗有用。